Johnson Fistel, PLLC is investigating potential securities fraud claims on behalf of investors in J.Jill, RH, and Viridian Therapeutics. The J.Jill investigation was prompted by the company's March 31, 2026 earnings disclosure revealing poor holiday assortment performance, increased competitive promotions, and customer migration toward discounted pricing, raising questions about compliance with federal securities laws.

Johnson Fistel, PLLP announced investigations into potential securities law violations by Viridian Therapeutics, Braskem S.A., and TAT Technologies Ltd. on behalf of investors who suffered losses. The investigation into Viridian focuses on whether the company complied with federal securities laws following its announcement of Phase 3 clinical trial results for its REVEAL-1 trial.

Commodore Capital completely exited its 3.2 million share position in Viridian Therapeutics (worth $69 million) on February 17, 2026, reducing the holding from 3.4% of the fund's assets to zero. This comes despite Viridian's stock being up 75% over the past year and entering a catalyst-heavy 2026 with FDA approval decisions and Phase 3 data expected. The exit suggests the fund may be taking profits after the strong rally or reallocating capital to other clinical-stage biotech names.

The biotech sector rebounded strongly in 2025 as M&A activity surged, becoming a stabilizing force for small and mid-cap companies. With 57% of biopharma acquisitions involving smaller firms and $30.9 billion in deals, investor sentiment shifted from GLP-1 drugs toward cancer and autoimmune disease treatments, particularly next-generation CAR-T therapies. Looking ahead to 2026, analysts expect continued M&A activity and strategic partnerships, though risks remain including FDA staff turnover and an 'IPO air pocket' from the 2023-2024 downturn.

Argenx discontinued its Phase 3 UplighTED studies evaluating efgartigimod for thyroid eye disease after an Independent Data Monitoring Committee recommended stopping the trials for futility, despite a favorable safety profile.

4D Molecular Therapeutics announced the appointment of Kristian Humer as Chief Financial Officer, bringing over two decades of finance and biotechnology experience to support the company's late-stage clinical development and commercial planning.

Over 20 pharmaceutical companies are actively developing new treatments for Thyroid Eye Disease (TED), a serious autoimmune inflammatory condition affecting orbital tissues. The clinical trial pipeline is expanding with promising therapies targeting various mechanisms of the disease.

Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.

Viridian Therapeutics reported Q2 2025 results, highlighting progress in thyroid eye disease treatment with veligrotug, securing FDA Breakthrough Therapy Designation and a $70 million licensing deal with Kissei Pharmaceutical, while experiencing increased research expenses and net losses.

The global ophthalmic disease therapeutics market is projected to grow significantly due to factors like the introduction of innovative treatments, rising disposable incomes, and expanding healthcare infrastructure. The market is segmented by indication, therapies, and distribution channel.

The thyroid eye disease market is expected to show good positive growth by 2034, driven by new product launches, a robust pipeline of emerging therapies, and an increase in the geriatric population.

7 analysts have expressed a variety of opinions on Viridian Therapeutics (NASDAQ:VRDN) over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 2 1 1 0 0 2M Ago 0 0 0 0 0 3M Ago 2 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Viridian Therapeutics, presenting an average target of $26.57, a high estimate of $31.00, and a low estimate of $20.00. A decline of 15.38% from the prior average price target is evident in the current average. Understanding Analyst Ratings: A Comprehensive Breakdown The standing of Viridian Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Richard Law Goldman Sachs Announces Buy $23.00 - Douglas Tsao HC Wainwright & Co. Lowers Buy $27.00 $37.00 Leland Gershell Oppenheimer Lowers Outperform $31.00 $36.00 Kalpit Patel B. Riley Securities Lowers Neutral $20.00 $25.00 Serge Belanger Needham Maintains Buy $30.00 - Kalpit Patel B. Riley Securities Lowers Buy $25.00 $29.00 Serge Belanger Needham Maintains Buy $30.00 $30.00 Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating ...Full story available on Benzinga.com